A case-control study evaluating occult blood screening for colorectal cancer with hemoccult test and an immunochemical hemagglutination test.
A case-control study evaluating occult blood screening for colorectal cancer with hemoccult test and an immunochemical hemagglutination test.
复制标题
一项病例对照研究，通过血潜试验和免疫化学血凝试验评估结直肠癌潜血筛查。
DOI：
10.3892/or.7.4.815
复制
发表时间：
2000
期刊：
影响因子：
4.2
通讯作者：
Akihiro Munakata
中科院分区：
文献类型：
--
作者：
Hisaki Saito;Yasushi Soma;M. Nakajima;J. Koeda;Hitoshi Kawaguchi;R. Kakizaki;R. Chiba;T. Aisawa;Akihiro Munakata
在一个城镇进行了一项病例对照研究，以评估结直肠癌的隐血筛查，该城镇早年通过隐血试验进行了结直肠癌筛查，随后通过免疫化学血凝试验进行了结直肠癌筛查。所有年龄≥ 40岁的居民都接受了年度筛查。病例系列包括51例致死性结直肠癌受试者。每个病例的三个对照组是从相应病例诊断时活着的居民名单中选出的，这些居民一直生活在该镇，按性别和年龄进行匹配。在病例诊断前1年和1-2年内有最近一次隐血试验或免疫化学试验筛查史的患者死于结直肠癌的比值比（OR）分别为0.20 [95%置信区间（CI）：0.08-0.49]和0.20 [95%置信区间（CI）：0.08-0.49]。17（95% CI：0.04-0.75）。随着距离最近一次筛查的年数增加，OR增加至1.0。在调整既往隐血试验筛选史后，在前1年内仅用免疫化学试验筛选的患者死于结直肠癌的OR计算为0.19（95%CI：0.05-0.70）。在前1年内接受过隐血试验筛查的患者的相应OR为0.36（95%CI：0.11-1.17）。这些结果表明，粪便隐血试验或免疫化学试验单独筛查结直肠癌将降低死亡率，免疫化学试验筛查的有效性将高于隐血试验。
A case control study to evaluate the occult blood screening for colorectal cancer was conducted in a town where colorectal cancer screening had been performed by Hemoccult test during the early years and subsequently by an immunochemical hemagglutination test. All residents aged >/=40 years had been offered the annual screening. Case series consisted of 51 subjects with fatal colorectal cancer. Three controls per case were selected from the list of residents who were alive at the time of diagnosis of the corresponding case and had been living in the town, matched by gender and by age. The odds ratio (OR) of dying of colorectal cancer for those having their most recent screening histories with Hemoccult test or the immunochemical test during the preceding 1 year and 1-2 year segment before case diagnosis were 0.20 [95% confidence interval (CI): 0.08-0.49] and 0. 17 (95% CI: 0.04-0.75), respectively. The OR increased towards 1.0 as the number of years since the most recent screening increased. The OR of dying of colorectal cancer was calculated to be 0.19 (95% CI: 0.05-0.70) for those screened with the immunochemical test alone during the preceding 1 year after adjustment for previous screening histories with the Hemoccult test. Corresponding OR was 0.36 (95% CI: 0.11-1.17) for those screened with Hemoccult test during the preceding 1 year. These results suggest that screening for colorectal cancer by fecal occult blood testings or immunochemical test alone would reduce mortality and that efficacy of the screening would be higher for the immunochemical test than for Hemoccult test.